Movatterモバイル変換


[0]ホーム

URL:


SG11202007164UA - Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) - Google Patents

Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)

Info

Publication number
SG11202007164UA
SG11202007164UASG11202007164UASG11202007164UASG11202007164UASG 11202007164U ASG11202007164U ASG 11202007164UASG 11202007164U ASG11202007164U ASG 11202007164UASG 11202007164U ASG11202007164U ASG 11202007164UASG 11202007164U ASG11202007164U ASG 11202007164UA
Authority
SG
Singapore
Prior art keywords
isonicotinyl
piperidine
trifluoromethyl
fluoro
preparing
Prior art date
Application number
SG11202007164UA
Inventor
Dengjin Wang
Pingli Liu
Yongzhong Wu
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte CorpfiledCriticalIncyte Corp
Publication of SG11202007164UApublicationCriticalpatent/SG11202007164UA/en

Links

Classifications

Landscapes

SG11202007164UA2018-01-302019-01-29Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)SG11202007164UA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201862623664P2018-01-302018-01-30
PCT/US2019/015582WO2019152374A1 (en)2018-01-302019-01-29Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)

Publications (1)

Publication NumberPublication Date
SG11202007164UAtrue SG11202007164UA (en)2020-08-28

Family

ID=65409599

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11202007164UASG11202007164UA (en)2018-01-302019-01-29Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)

Country Status (35)

CountryLink
US (1)US10899736B2 (en)
EP (2)EP3746429B1 (en)
JP (2)JP7393348B2 (en)
KR (1)KR102732167B1 (en)
CN (1)CN112105608B (en)
AR (1)AR114810A1 (en)
AU (1)AU2019213665B2 (en)
BR (1)BR112020015470A2 (en)
CA (1)CA3089832A1 (en)
CL (1)CL2020001983A1 (en)
CO (1)CO2020009994A2 (en)
CR (1)CR20200379A (en)
CY (1)CY1125207T1 (en)
DK (1)DK3746429T3 (en)
EA (1)EA202091830A1 (en)
ES (1)ES2912469T3 (en)
HR (1)HRP20220510T1 (en)
IL (1)IL276302B2 (en)
LT (1)LT3746429T (en)
MA (1)MA51771B1 (en)
MD (1)MD3746429T2 (en)
MX (1)MX2020007973A (en)
MY (1)MY203122A (en)
PE (1)PE20211310A1 (en)
PH (1)PH12020551145A1 (en)
PL (1)PL3746429T3 (en)
PT (1)PT3746429T (en)
RS (1)RS63312B1 (en)
SG (1)SG11202007164UA (en)
SI (1)SI3746429T1 (en)
SM (1)SMT202200195T1 (en)
TW (1)TWI797242B (en)
UA (1)UA127488C2 (en)
WO (1)WO2019152374A1 (en)
ZA (1)ZA202004692B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2019213665B2 (en)2018-01-302024-06-13Incyte CorporationProcesses for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CN118557580A (en)2018-02-162024-08-30因赛特公司JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2019191679A1 (en)2018-03-302019-10-03Incyte CorporationBiomarkers for inflammatory skin disease
MX2020010815A (en)2018-04-132020-12-11Incyte CorpBiomarkers for graft-versus-host disease.
CA3117969A1 (en)2018-10-312020-05-07Incyte CorporationCombination therapy for treatment of hematological diseases
US11406640B2 (en)2019-03-052022-08-09Incyte CorporationJAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP4041204A1 (en)2019-10-102022-08-17Incyte CorporationBiomarkers for graft-versus-host disease
US12360120B2 (en)2019-10-102025-07-15Incyte CorporationBiomarkers for graft-versus-host disease
US11992490B2 (en)2019-10-162024-05-28Incyte CorporationUse of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN110683978A (en)*2019-10-302020-01-14西安医学院 A kind of preparation method of 3-nitrile methylene azetidine-1-tert-butyl carbonate
US11897889B2 (en)2020-08-182024-02-13Incyte CorporationProcess and intermediates for preparing a JAK1 inhibitor
PE20231743A1 (en)2020-08-182023-10-31Incyte Corp PROCESS AND INTERMEDIARIES TO PREPARE A JAK INHIBITOR
KR20230118118A (en)2020-12-082023-08-10인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of vitiligo
CN112625030A (en)*2020-12-252021-04-09杭州澳赛诺生物科技有限公司Synthetic method for synthesizing N-protected 3-bromopyrazole by one-pot method
US12268667B2 (en)2021-05-032025-04-08Incyte CorporationJAK1 pathway inhibitors for the treatment of prurigo nodularis
CA3226714A1 (en)2021-07-122023-01-19Incyte CorporationProcess and intermediates for preparing baricitinib
WO2024222835A1 (en)*2023-04-272024-10-31Sironax Ltd.Sarm1 modulators, preparations, and uses thereof

Family Cites Families (283)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2985589A (en)1957-05-221961-05-23Universal Oil Prod CoContinuous sorption process employing fixed bed of sorbent and moving inlets and outlets
US3832460A (en)1971-03-191974-08-27C KostiAnesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en)1976-02-131979-02-20Hoffmann-La Roche Inc.Sustained release tablet formulations
DE3036390A1 (en)1980-09-261982-05-13Troponwerke GmbH & Co KG, 5000 KölnAntiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid
DE3220113A1 (en)1982-05-281983-12-01Basf Ag, 6700 Ludwigshafen DIFLUORMETHOXIPHENYLTHIOPHOSPHORSAEUREESTER
US4402832A (en)1982-08-121983-09-06Uop Inc.High efficiency continuous separation process
US4548990A (en)1983-08-151985-10-22Ciba-Geigy CorporationCrosslinked, porous polymers for controlled drug delivery
US4498991A (en)1984-06-181985-02-12Uop Inc.Serial flow continuous separation process
NL8403224A (en)1984-10-241986-05-16Oce Andeno Bv DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
CA1306260C (en)1985-10-181992-08-11Shionogi & Co., Ltd.Condensed imidazopyridine derivatives
ATE139232T1 (en)1989-10-111996-06-15Teijin Ltd BIZYCLIC PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
IT1258781B (en)1992-01-161996-02-29Zambon Spa OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYLCISTEIN AND POLYVINYL ALCOHOL
US5521184A (en)1992-04-031996-05-28Ciba-Geigy CorporationPyrimidine derivatives and processes for the preparation thereof
AU671491B2 (en)1992-12-181996-08-29F. Hoffmann-La Roche AgN-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JPH0710876A (en)1993-06-241995-01-13Teijin LtdPyrrolo(2,3-d)pyrimidine having cyclic amino group at 4-position
EP0727217A3 (en)1995-02-101997-01-15Suntory LtdPharmaceutical composition containing god-type ellagitannin as active ingredient
IL117580A0 (en)1995-03-291996-07-23Merck & Co IncInhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5856326A (en)1995-03-291999-01-05Merck & Co., Inc.Inhibitors of farnesyl-protein transferase
BR9609613A (en)1995-07-051999-05-25Du Pont Compound fungicidal composition and method of controlling plant diseases
US5630943A (en)1995-11-301997-05-20Merck Patent Gesellschaft Mit Beschrankter HaftungDiscontinuous countercurrent chromatographic process and apparatus
TW531537B (en)1995-12-272003-05-11Janssen Pharmaceutica Nv1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
GB9604361D0 (en)1996-02-291996-05-01Pharmacia Spa4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU727939B2 (en)1996-04-032001-01-04Merck & Co., Inc.A method of treating cancer
CA2251955A1 (en)1996-04-181997-10-23Nancy E. KohlA method of treating cancer
US5795909A (en)1996-05-221998-08-18Neuromedica, Inc.DHA-pharmaceutical agent conjugates of taxanes
EP0934270A1 (en)1996-05-301999-08-11Merck & Co., Inc.A method of treating cancer
US6624138B1 (en)2001-09-272003-09-23Gp MedicalDrug-loaded biological material chemically treated with genipin
EP0973396A4 (en)1997-04-072001-02-07Merck & Co IncA method of treating cancer
US6063284A (en)1997-05-152000-05-16Em Industries, Inc.Single column closed-loop recycling with periodic intra-profile injection
US6060038A (en)1997-05-152000-05-09Merck & Co., Inc.Radiolabeled farnesyl-protein transferase inhibitors
WO1999007379A1 (en)1997-08-111999-02-18Boehringer Ingelheim Pharmaceuticals, Inc.5,6-HETEROARYL-DIPYRIDO[2,3-b:3',2'-f]AZEPINES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION
US6075056A (en)1997-10-032000-06-13Penederm, Inc.Antifungal/steroid topical compositions
US6025366A (en)1998-04-022000-02-15Merck & Co., Inc.Antagonists of gonadotropin releasing hormone
JP2002517396A (en)1998-06-042002-06-18アボット・ラボラトリーズ Anti-inflammatory compounds that inhibit cell adhesion
US6232320B1 (en)1998-06-042001-05-15Abbott LaboratoriesCell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (en)1998-06-192000-09-29Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
BR9912938B1 (en)1998-08-112011-06-28 isoquinoline derivatives, composition comprising them, process for preparation and use thereof.
JP2000119271A (en)1998-08-122000-04-25Hokuriku Seiyaku Co Ltd 1H-imidazopyridine derivative
JP5026635B2 (en)1998-09-102012-09-12ニュコメデ ダンマルク アンパーツセルスカブ Rapid release pharmaceutical composition of pharmaceutical substance
FR2785196B1 (en)1998-10-292000-12-15Inst Francais Du Petrole METHOD AND DEVICE FOR SEPARATION WITH VARIABLE LENGTH CHROMATOGRAPHIC AREAS
US6413419B1 (en)1998-10-292002-07-02Institut Francais Du PetroleProcess and device for separation with variable-length chromatographic
US6375839B1 (en)1998-10-292002-04-23Institut Francais Du PetroleProcess and device for separation with variable-length chromatographic zones
US6133031A (en)1999-08-192000-10-17Isis Pharmaceuticals Inc.Antisense inhibition of focal adhesion kinase expression
AU3248600A (en)1999-03-032000-09-21Merck & Co., Inc.Inhibitors of prenyl-protein transferases
GB9905075D0 (en)1999-03-061999-04-28Zeneca LtdChemical compounds
US6217895B1 (en)1999-03-222001-04-17Control Delivery SystemsMethod for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en)1999-03-312001-05-29Insite Vision, IncorporatedTopical treatment or prevention of ocular infections
WO2000063168A1 (en)1999-04-162000-10-26Coelacanth Chemical CorporationSynthesis of azetidine derivatives
US6921763B2 (en)1999-09-172005-07-26Abbott LaboratoriesPyrazolopyrimidines as therapeutic agents
US6699880B1 (en)1999-10-132004-03-02Banyu Pharmaceutical Co., Ltd.Substituted imidazolidinone derivatives
HU229671B1 (en)1999-12-102014-04-28Pfizer Prod IncPyrrolo[2,3-d]pirimidine compounds
EA005212B1 (en)1999-12-242004-12-30Авентис Фарма ЛимитедAzaindoles
GB0004890D0 (en)2000-03-012000-04-19Astrazeneca Uk LtdChemical compounds
US7235551B2 (en)2000-03-022007-06-26Smithkline Beecham Corporation1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DK1142566T3 (en)2000-04-072004-02-09Medidom Lab Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate
WO2001081345A1 (en)2000-04-202001-11-01Mitsubishi Pharma CorporationAromatic amide compounds
CA2406278C (en)2000-04-252012-06-05Icos CorporationInhibitors of human phosphatidyl-inositol 3-kinase delta
US7498304B2 (en)2000-06-162009-03-03Curis, Inc.Angiogenesis-modulating compositions and uses
IL153115A0 (en)2000-06-162003-06-24Curis IncAngiogenesis-modulating compositions and uses
US6335342B1 (en)2000-06-192002-01-01Pharmacia & Upjohn S.P.A.Azaindole derivatives, process for their preparation, and their use as antitumor agents
WO2001097849A1 (en)2000-06-232001-12-27Mitsubishi Pharma CorporationAntitumor effect potentiators
KR100516419B1 (en)2000-06-262005-09-23화이자 프로덕츠 인크.Pyrrolo[2,3-d]pyrimidine Compounds as Immunosuppressive Agents
SI1294358T1 (en)2000-06-282004-12-31Smithkline Beecham PlcWet milling process
MXPA03005001A (en)2000-12-052003-09-05Vertex PharmaInhibitors of c-jun n-terminal kinases (jnk) and other protein kinases.
GB0100622D0 (en)2001-01-102001-02-21Vernalis Res LtdChemical compounds V111
JP2004520347A (en)2001-01-152004-07-08グラクソ グループ リミテッド Arylpiperidine and piperazine derivatives as inducers of LDL-receptor expression
EP1363702A4 (en)2001-01-302007-08-22Cytopia Pty LtdMethods of inhibiting kinases
US6884804B2 (en)2001-05-162005-04-26Vertex Pharmaceuticals IncorporatedInhibitors of Src and other protein kinases
US7301023B2 (en)2001-05-312007-11-27Pfizer Inc.Chiral salt resolution
GB0115109D0 (en)2001-06-212001-08-15Aventis Pharma LtdChemical compounds
GB0115393D0 (en)2001-06-232001-08-15Aventis Pharma LtdChemical compounds
DE60216115T2 (en)2001-08-012007-05-31Merck & Co., Inc. BENZIMIDAZO 4,5-föISOCHINOLINONE DERIVATIVES
AU2002337142B2 (en)2001-09-192007-10-11Aventis Pharma S.A.Indolizines as kinase protein inhibitors
US6429231B1 (en)2001-09-242002-08-06Bradley Pharmaceuticals, Inc.Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
JP4959918B2 (en)2001-10-302012-06-27ノバルティス アーゲー Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
JP2003155285A (en)2001-11-192003-05-27Toray Ind IncCyclic nitrogen-containing derivative
CA2468942A1 (en)2001-11-302003-06-12Teijin LimitedProcess for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound
GT200200234A (en)2001-12-062003-06-27 NEW CRYSTAL COMPOUNDS
US6995144B2 (en)2002-03-142006-02-07Eisai Co., Ltd.Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en)2002-04-192004-03-01Bristol Myers Squibb CoHeterocyclo inhibitors of potassium channel function
WO2003091246A1 (en)2002-04-262003-11-06Vertex Pharmaceuticals IncorporatedPyrrole derivatives as inhibitors of erk2 and uses thereof
CA2483084A1 (en)2002-05-022003-11-13Merck & Co., Inc.Tyrosine kinase inhibitors
WO2003094888A1 (en)2002-05-072003-11-20Control Delivery Systems, Inc.Processes for forming a drug delivery device
WO2003099796A1 (en)2002-05-232003-12-04Cytopia Pty LtdProtein kinase inhibitors
AR037647A1 (en)2002-05-292004-12-01Novartis Ag USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase
CN1630668A (en)2002-06-262005-06-22出光兴产株式会社Hydrogenated copolymer, process for producing the same, and hot melt adhesive composition comprising the same
GB0215676D0 (en)2002-07-052002-08-14Novartis AgOrganic compounds
GB0215844D0 (en)2002-07-092002-08-14Novartis AgOrganic compounds
US20060004010A1 (en)2002-07-102006-01-05Hiromu HabashitaCcr4 antagonist and medical use thereof
CA2497977A1 (en)2002-09-202004-04-01Alcon, Inc.Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040204404A1 (en)2002-09-302004-10-14Robert ZelleHuman N-type calcium channel blockers
ES2289349T3 (en)2002-11-042008-02-01Vertex Pharmaceuticals Incorporated DERIVATIVES OF HETEROARIL-PYRIMIDINE AS JAK INHIBITORS.
AR042052A1 (en)2002-11-152005-06-08Vertex Pharma USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
US20040099204A1 (en)2002-11-252004-05-27Nestor John J.Sheet, page, line, position marker
CN1717236A (en)2002-11-262006-01-04辉瑞产品公司 Methods of treating transplant rejection
UA80767C2 (en)2002-12-202007-10-25Pfizer Prod IncPyrimidine derivatives for the treatment of abnormal cell growth
UY28126A1 (en)2002-12-242004-06-30Alcon Inc USE OF SELECTIVE GLUCOCORTICOIDS FOR THE EYE SURFACE IN THE TREATMENT OF EYE DROUGHT
US7135493B2 (en)2003-01-132006-11-14Astellas Pharma Inc.HDAC inhibitor
US7444183B2 (en)2003-02-032008-10-28Enteromedics, Inc.Intraluminal electrode apparatus and method
CA2515132C (en)2003-02-072012-01-03Vertex Pharmaceuticals IncorporatedHeteroaryl substituted pyrroles useful as inhibitors of protein kinases
GB0305929D0 (en)2003-03-142003-04-23Novartis AgOrganic compounds
CA2522595A1 (en)2003-04-032004-10-28Vertex Pharmaceuticals IncorporatedCompositions useful as inhibitors of protein kinases
SE0301372D0 (en)2003-05-092003-05-09Astrazeneca Ab Novel compounds
SE0301373D0 (en)2003-05-092003-05-09Astrazeneca Ab Novel compounds
FR2857454B1 (en)2003-07-082006-08-11Aventis Pasteur DOSAGE OF TECHIC ACIDS OF BACTERIA GRAM +
US20050043346A1 (en)2003-08-082005-02-24Pharmacia Italia S.P.A.Pyridylpyrrole derivatives active as kinase inhibitors
US8362017B2 (en)2003-08-292013-01-29Exelixis, Inc.C-kit modulators and methods of use
EP1678147B1 (en)2003-09-152012-08-08Lead Discovery Center GmbHPharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
AR045944A1 (en)2003-09-242005-11-16Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
US7358255B2 (en)2003-10-242008-04-15Santen Pharmaceutical Co., Ltd.Therapeutic agent for keratoconjunctival disorder
MY141220A (en)2003-11-172010-03-31Astrazeneca AbPyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005051393A1 (en)2003-11-252005-06-09Pfizer Products Inc.Method of treatment of atherosclerosis
CN1893952A (en)2003-12-172007-01-10辉瑞产品公司Pyrrolo[2,3-D]pyrimidine compounds for treating transplant rejection
JP4939229B2 (en)2003-12-192012-05-23シェーリング コーポレイション Thiadiazole as CXC-chemokine receptor ligand and CC-chemokine receptor ligand
US7504509B2 (en)2003-12-192009-03-17Plexxikon, Inc.Compounds and methods for development of Ret modulators
WO2005061463A1 (en)2003-12-232005-07-07Astex Therapeutics LimitedPyrazole derivatives as protein kinase modulators
US20050239806A1 (en)2004-01-132005-10-27Ambit Biosciences CorporationPyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2559285A1 (en)2004-03-182005-09-29Brigham And Women's Hospital, Inc.Methods for the treatment of synucleinopathies
AR048454A1 (en)2004-03-302006-04-26Vertex Pharma USEFUL AZAINDOLS AS INHIBITORS OF JAK PROTEIN KINES OR OTHER KINASE PROTEINS
AU2005249380C1 (en)2004-04-232012-09-20Exelixis, Inc.Kinase modulators and methods of use
WO2005105814A1 (en)2004-04-282005-11-10Incyte CorporationTetracyclic inhibitors of janus kinases
WO2005105988A2 (en)2004-04-282005-11-10Vertex Pharmaceuticals IncorporatedCrystal structure of human jak3 kinase domain complex and binding pockets thereof
WO2005105146A1 (en)2004-05-032005-11-10Novartis AgCombinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
WO2005110410A2 (en)2004-05-142005-11-24Abbott LaboratoriesKinase inhibitors as therapeutic agents
PE20060426A1 (en)2004-06-022006-06-28Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
ES2396135T3 (en)2004-06-102013-02-19Irm Llc Compounds and compositions as protein kinase inhibitors
EP1760071A4 (en)2004-06-232008-03-05Ono Pharmaceutical CoCompound having s1p receptor binding potency and use thereof
EP1765819B1 (en)2004-06-302014-03-12Vertex Pharmaceuticals Inc.Azaindoles useful as inhibitors of protein kinases
US7138423B2 (en)2004-07-202006-11-21Bristol-Myers Squibb CompanyArylpyrrolidine derivatives as NK-1 /SSRI antagonists
FR2873691B1 (en)2004-07-292006-10-06Sanofi Synthelabo AMINO-PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2006013114A1 (en)2004-08-062006-02-09Develogen AktiengesellschaftUse of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
CN101006186A (en)2004-08-232007-07-25财团法人牧岩生命工学研究所Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof
US20070054916A1 (en)2004-10-012007-03-08Amgen Inc.Aryl nitrogen-containing bicyclic compounds and methods of use
PT1802625E (en)2004-10-132008-08-06Hoffmann La RocheDisubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
UY29177A1 (en)2004-10-252006-05-31Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
MY179032A (en)2004-10-252020-10-26Cancer Research Tech LtdOrtho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101094853B (en)2004-11-042011-07-13沃泰克斯药物股份有限公司 Pyrazolo[1,5-a]pyrimidines useful as protein kinase inhibitors
MX2007006204A (en)2004-11-242007-06-20Novartis AgCombinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors.
US7517870B2 (en)2004-12-032009-04-14Fondazione TelethonUse of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20060128803A1 (en)2004-12-142006-06-15Alcon, Inc.Method of treating dry eye disorders using 13(S)-HODE and its analogs
WO2006067445A2 (en)2004-12-222006-06-29Astrazeneca AbCsf-1r kinase inhibitors
AR054416A1 (en)2004-12-222007-06-27Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US20090124635A1 (en)2005-01-202009-05-14Pfizer Inc.Chemical compounds
RU2434871C2 (en)2005-02-032011-11-27Вертекс Фармасьютикалз ИнкорпорейтедPyrrolopyrimidines used as protein kinase inhibitors
WO2007044050A2 (en)2005-02-042007-04-19Bristol-Myers Squibb Company1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2006101783A2 (en)2005-03-152006-09-28Irm LlcCompounds and compositions as protein kinase inhibitors
US20070021443A1 (en)2005-04-052007-01-25Ohlmeyer Michael JPurine and imidazopyridine derivatives for immunosuppression
GB0510139D0 (en)2005-05-182005-06-22Addex Pharmaceuticals SaNovel compounds B1
GB0510390D0 (en)2005-05-202005-06-29Novartis AgOrganic compounds
WO2006127587A1 (en)2005-05-202006-11-30Vertex Pharmaceuticals IncorporatedPyrrolopyridines useful as inhibitors of protein kinase
ES2651349T3 (en)2005-06-082018-01-25Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
WO2006136823A1 (en)2005-06-212006-12-28Astex Therapeutics LimitedHeterocyclic containing amines as kinase b inhibitors
UA95244C2 (en)2005-06-222011-07-25Плексикон, Инк.Compounds and methods for kinase modulation, and indications therefor
CN102127078A (en)2005-07-142011-07-20安斯泰来制药株式会社Heterocyclic janus kinase 3 inhibitors
FR2889662B1 (en)2005-08-112011-01-14Galderma Res & Dev OIL-IN-WATER EMULSION FOR TOPICAL APPLICATION IN DERMATOLOGY
WO2007025090A2 (en)2005-08-252007-03-01Kalypsys, Inc.Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1926735A1 (en)2005-09-222008-06-04Incyte CorporationTetracyclic inhibitors of janus kinases
AU2006297351A1 (en)2005-09-302007-04-12Vertex Pharmaceuticals IncorporatedDeazapurines useful as inhibitors of janus kinases
US20070128633A1 (en)2005-10-112007-06-07Chembridge Research Laboratories, Inc.Cell-free protein expression systems and methods of use thereof
WO2007043677A1 (en)2005-10-142007-04-19Sumitomo Chemical Company, LimitedHydrazide compound and pesticidal use of the same
NZ567300A (en)*2005-10-192010-11-26Kissei PharmaceuticalFused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
AU2006307657B2 (en)2005-10-282010-10-28Astrazeneca Ab4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007053452A1 (en)2005-11-012007-05-10Targegen, Inc.Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007062459A1 (en)2005-11-292007-06-07Cytopia Research Pty LtdSelective kinase inhibitors based on pyridine scaffold
PT2455382T (en)2005-12-132017-01-31Incyte Holdings Corp PYRIDOLES [2,3-B] PYRIDINES AND PYRROLE [2,3-B] PYRIMIDINES SUBSTITUTED BY HETEROARYLO AS JANUS KINASES INHIBITORS
US20130137681A1 (en)2005-12-132013-05-30Incyte CorporationHETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
EP1968568A4 (en)2005-12-222011-04-13Glaxosmithkline LlcINHIBITORS OF Akt ACTIVITY
PL1962830T3 (en)2005-12-232013-08-30Glaxosmithkline LlcAzaindole inhibitors of aurora kinases
TW201412738A (en)2006-01-172014-04-01Vertex PharmaAzaindoles useful as inhibitors of janus kinases
TW200738709A (en)2006-01-192007-10-16Osi Pharm IncFused heterobicyclic kinase inhibitors
US20090018156A1 (en)2006-02-012009-01-15Jun TangPyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors
US7745477B2 (en)2006-02-072010-06-29Hoffman-La Roche Inc.Heteroaryl and benzyl amide compounds
KR20090008217A (en)2006-03-102009-01-21오노 야꾸힝 고교 가부시키가이샤 Nitrogen-containing heterocyclic derivatives and drugs containing these as active ingredients
EP2003132B1 (en)2006-04-032014-03-05Astellas Pharma Inc.Oxadiazole derivatives as S1P1 agonists
AU2007235487A1 (en)2006-04-052007-10-18Vertex Pharmaceuticals IncorporatedDeazapurines useful as inhibitors of janus kinases
WO2007116313A2 (en)2006-04-122007-10-18Pfizer LimitedPyrrolidine derivatives as modulators of chemokine ccr5 receptors
WO2007129195A2 (en)2006-05-042007-11-15Pfizer Products Inc.4-pyrimidine-5-amino-pyrazole compounds
EP2040704A2 (en)2006-05-182009-04-01Bayer Healthcare AgPharmaceutical compositions comprising implitapide and methods of using same
US7691811B2 (en)2006-05-252010-04-06Bodor Nicholas STransporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
TWI398252B (en)2006-05-262013-06-11Novartis AgPyrrolopyrimidine compounds and their uses
US20080021217A1 (en)2006-07-202008-01-24Allen BorchardtHeterocyclic inhibitors of rho kinase
WO2008013622A2 (en)2006-07-272008-01-31E. I. Du Pont De Nemours And CompanyFungicidal azocyclic amides
WO2008016123A1 (en)2006-08-032008-02-07Takeda Pharmaceutical Company LimitedGSK-3β INHIBITOR
CA2660560A1 (en)2006-08-162008-02-21Boehringer Ingelheim International GmbhPyrazine compounds, their use and methods of preparation
MX2009002558A (en)2006-09-082009-03-20Novartis AgN-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions.
WO2008035376A2 (en)2006-09-192008-03-27Council Of Scientific & Industrial ResearchA novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof
AR063141A1 (en)2006-10-042008-12-30Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
US7919490B2 (en)2006-10-042011-04-05Wyeth Llc6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20120225057A1 (en)2006-10-112012-09-06Deciphera Pharmaceuticals, LlcMethods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
AU2007316417B2 (en)2006-11-062013-08-22Tolero Pharmaceuticals, Inc.Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20080119496A1 (en)2006-11-162008-05-22Pharmacopeia Drug Discovery, Inc.7-Substituted Purine Derivatives for Immunosuppression
EP3034075B1 (en)2006-11-222018-07-25Incyte Holdings CorporationImidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008067119A2 (en)2006-11-272008-06-05Smithkline Beecham CorporationNovel compounds
NZ577111A (en)2006-12-152012-05-25Abbott LabNovel oxadiazole compounds
AU2007338792B2 (en)2006-12-202012-05-31Amgen Inc.Substituted heterocycles and methods of use
ES2387471T3 (en)2006-12-202012-09-24Amgen Inc. Heterocyclic compounds and their use in the treatment of inflammation, angiogenesis and cancer
WO2008079965A1 (en)2006-12-222008-07-03Incyte CorporationSubstituted heterocycles as janus kinase inhibitors
CA2667072C (en)2006-12-222015-11-24Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.Gel useful for the delivery of ophthalmic drugs
JP2008179621A (en)2006-12-282008-08-07Taisho Pharmaceutical Co Ltd Nitrogen-containing saturated heterocyclic compounds
WO2008082839A2 (en)2006-12-292008-07-10Abbott LaboratoriesPim kinase inhibitors as cancer chemotherapeutics
WO2008082840A1 (en)2006-12-292008-07-10Abbott LaboratoriesPim kinase inhibitors as cancer chemotherapeutics
KR20080062876A (en)2006-12-292008-07-03주식회사 대웅제약 Novel Antifungal Triazole Derivatives
CA2679659C (en)2007-03-012016-01-19Novartis AgPim kinase inhibitors and methods of their use
RS52862B (en)2007-04-032013-12-31Array Biopharma Inc.Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
GB0709031D0 (en)2007-05-102007-06-20Sareum LtdPharmaceutical compounds
WO2008145681A2 (en)2007-05-312008-12-04Boehringer Ingelheim International GmbhCcr2 receptor antagonists and uses thereof
GB0710528D0 (en)2007-06-012007-07-11Glaxo Group LtdNovel compounds
ES2903444T3 (en)2007-06-132022-04-01Incyte Holdings Corp Use of Janus(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile kinase inhibitor salts
CL2008001709A1 (en)2007-06-132008-11-03Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
US8541426B2 (en)2007-07-112013-09-24Pfizer Inc.Pharmaceutical compositions and methods of treating dry eye disorders
AP2010005167A0 (en)2007-08-012010-02-28PfizerPyrazole compounds and their use as RAF inhibitors
WO2009049028A1 (en)2007-10-092009-04-16Targegen Inc.Pyrrolopyrimidine compounds and their use as janus kinase modulators
US20110263664A1 (en)2007-11-152011-10-27Musc Foundation For Research DevelopmentInhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
JP5480813B2 (en)2007-11-162014-04-23インサイト・コーポレイション Substituted heterocycles as JANUS kinase inhibitors
GB0723815D0 (en)2007-12-052008-01-16Glaxo Group LtdCompounds
LT2231689T (en)2008-01-182016-10-25Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech RepublicNovel cytostatic 7-deazapurine nucleosides
BRPI0905952A2 (en)2008-02-042015-06-30Mercury Therapeutics Compound and salts thereof and pharmaceutical composition
AR070531A1 (en)2008-03-032010-04-14Novartis Ag PIM KINASE INHIBITORS AND METHODS FOR USE
SI2288610T1 (en)2008-03-112016-11-30Incyte Holdings CorporationAzetidine and cyclobutane derivatives as jak inhibitors
BRPI0908906A2 (en)2008-03-212019-09-24Novartis Ag heterocyclic compounds and their uses
CN102076333A (en)2008-06-262011-05-25安特里奥公司Dermal delivery
TWI461423B (en)2008-07-022014-11-21Astrazeneca AbThiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
FR2933409B1 (en)2008-07-032010-08-27Centre Nat Rech Scient NEW PYRROLO ° 2,3-a! CARBAZOLES AND THEIR USE AS INHIBITORS OF PIM KINASES
TWI496779B (en)2008-08-192015-08-21Array Biopharma IncTriazolopyridine compounds as pim kinase inhibitors
WO2010022081A1 (en)2008-08-192010-02-25Array Biopharma Inc.Triazolopyridine compounds as pim kinase inhibitors
JP4884570B2 (en)2008-08-202012-02-29ファイザー・インク Pyrrolo [2,3-d] pyrimidine compound
SI2344474T1 (en)2008-09-022015-12-31Novartis AgPicolinamide derivatives as kinase inhibitors
KR20110056399A (en)2008-09-022011-05-27노파르티스 아게 Heterocyclic PIM-Kinase Inhibitors
MX2011002367A (en)2008-09-022011-04-04Novartis AgBicyclic kinase inhibitors.
CL2009001884A1 (en)2008-10-022010-05-14Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
CA2739466A1 (en)2008-10-172010-04-22Merck Frosst Canada Ltd.Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JOP20190230A1 (en)2009-01-152017-06-16Incyte Corp Methods for repairing JAK inhibitors and related intermediates
EP2210890A1 (en)2009-01-192010-07-28Almirall, S.A.Oxadiazole derivatives as S1P1 receptor agonists
US8263601B2 (en)2009-02-272012-09-11Concert Pharmaceuticals, Inc.Deuterium substituted xanthine derivatives
TW201100429A (en)2009-05-222011-01-01Incyte CorpN-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2010135621A1 (en)2009-05-222010-11-25Incyte Corporation3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
UA110324C2 (en)2009-07-022015-12-25Genentech IncJak inhibitory compounds based on pyrazolo pyrimidine
EP2470534A4 (en)2009-08-242013-02-27Merck Sharp & Dohme INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA
TW201111385A (en)2009-08-272011-04-01Biocryst Pharm IncHeterocyclic compounds as janus kinase inhibitors
AR078012A1 (en)2009-09-012011-10-05Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
EP2475659B1 (en)2009-09-082015-10-28F.Hoffmann-La Roche Ag4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2305660A1 (en)2009-09-252011-04-06Almirall, S.A.New thiadiazole derivatives
CN105541847B (en)2009-10-092019-08-16因西特控股公司The hydroxy derivatives, ketone group derivative and glucuronide of 3- (4- (7H- pyrrolo- [2,3-d] pyrimidine-4-yl) -1H- pyrazol-1-yl) -3- cyclopenta propionitrile
CN102666545B (en)2009-10-202016-04-06塞尔卓姆有限公司As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor
EP2332917B1 (en)2009-11-112012-08-01Sygnis Bioscience GmbH & Co. KGCompounds for PIM kinase inhibition and for treating malignancy
US9724410B2 (en)2009-11-242017-08-08Alderbio Holdings LlcAnti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
WO2011069141A2 (en)2009-12-042011-06-09Board Of Regents, The University Of Texas SystemInterferon therapies in combination with blockade of stat3 activation
US8461328B2 (en)2010-01-122013-06-11Genentech, Inc.Tricyclic heterocyclic compounds, compositions and methods of use thereof
SA111320200B1 (en)2010-02-172014-02-16ديبيوفارم اس ايهBicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
EP2536729A1 (en)2010-02-182012-12-26Incyte CorporationCyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
TWI592413B (en)2010-03-102017-07-21英塞特公司Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CN102822546B (en)*2010-03-302015-10-14Ntn株式会社Rolling bearing
NZ603446A (en)2010-04-142014-05-30Array Biopharma Inc5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2390252A1 (en)2010-05-192011-11-30Almirall, S.A.New pyrazole derivatives
UA111588C2 (en)2010-05-212016-05-25Інсайт Холдінгс Корпорейшн JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION
US8637529B2 (en)2010-06-112014-01-28AbbYie Inc.Pyrazolo[3,4-d]pyrimidine compounds
WO2012003457A1 (en)2010-07-012012-01-05Mtm Research LlcAnti-fibroblastic fluorochemical emulsion therapies
US20130252917A1 (en)2010-09-302013-09-26Portola Pharmaceuticals, Inc.Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
EP2640725B1 (en)2010-11-192015-01-07Incyte CorporationHeterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012068450A1 (en)2010-11-192012-05-24Incyte CorporationCyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20140073643A1 (en)2010-12-032014-03-13Ym Biosciences Australia Pty LtdTreatment of jak2-mediated conditions
CA2827673C (en)2011-02-182020-10-27Novartis Pharma AgMtor/jak inhibitor combination therapy
AU2012273164B2 (en)2011-06-202015-05-28Incyte Holdings CorporationAzetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CA2844507A1 (en)2011-08-102013-02-14Novartis Pharma AgJak pi3k/mtor combination therapy
TW201313721A (en)2011-08-182013-04-01Incyte CorpCyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en)*2011-09-072016-06-24Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
WO2013173720A1 (en)*2012-05-182013-11-21Incyte CorporationPiperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US10155987B2 (en)2012-06-122018-12-18Dana-Farber Cancer Institute, Inc.Methods of predicting resistance to JAK inhibitor therapy
EP2890691B1 (en)2012-08-312018-04-25Principia Biopharma Inc.Benzimidazole derivatives as itk inhibitors
CN107936039A (en)2012-11-012018-04-20因赛特公司Tricyclic condensed thiophene derivant as JAK inhibitor
ES2880814T3 (en)2012-11-152021-11-25Incyte Holdings Corp Ruxolitinib Sustained Release Dosage Forms
CR20190518A (en)*2013-03-062020-01-10Incyte CorpProcesses and intermediates for making a jak inhibitor
TWI644671B (en)*2013-03-142018-12-21比利時商健生藥品公司 P2X7 regulator
BR112015028501B8 (en)2013-05-172023-01-24Incyte Corp BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
KR20160045081A (en)2013-08-072016-04-26인사이트 코포레이션Sustained release dosage forms for a jak1 inhibitor
CN105555313A (en)2013-08-202016-05-04因赛特公司Survival benefit in patients with solid tumors with elevated c-reactive protein levels
WO2015131031A1 (en)2014-02-282015-09-03Incyte CorporationJak1 inhibitors for the treatment of myelodysplastic syndromes
UA119767C2 (en)2014-04-082019-08-12Інсайт КорпорейшнTreatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (en)2014-04-302016-07-16英塞特公司Processes of preparing a JAK1 inhibitor and new forms thereto
EP3148545B1 (en)2014-05-282023-03-15Onco Tracker, Inc.Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US9498467B2 (en)2014-05-302016-11-22Incyte CorporationTreatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105524067A (en)*2014-09-282016-04-27江苏柯菲平医药股份有限公司4-substituted pyrrolo[2,3-d]pyrimidine compound and uses thereof
AU2019213665B2 (en)2018-01-302024-06-13Incyte CorporationProcesses for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)

Also Published As

Publication numberPublication date
MA51771A (en)2020-12-09
JP2024023173A (en)2024-02-21
DK3746429T3 (en)2022-05-02
PT3746429T (en)2022-06-20
JP7707254B2 (en)2025-07-14
JP7393348B2 (en)2023-12-06
KR102732167B1 (en)2024-11-22
BR112020015470A2 (en)2020-12-08
SMT202200195T1 (en)2022-07-21
EA202091830A1 (en)2020-12-29
CO2020009994A2 (en)2020-10-30
CY1125207T1 (en)2024-12-13
UA127488C2 (en)2023-09-06
TW201940475A (en)2019-10-16
PH12020551145A1 (en)2021-05-31
US20190233392A1 (en)2019-08-01
AR114810A1 (en)2020-10-21
SI3746429T1 (en)2023-01-31
CN112105608B (en)2023-07-14
PE20211310A1 (en)2021-07-22
KR20200129099A (en)2020-11-17
ES2912469T3 (en)2022-05-26
LT3746429T (en)2022-05-10
CR20200379A (en)2021-03-05
HRP20220510T1 (en)2022-05-27
MY203122A (en)2024-06-10
IL276302B2 (en)2023-11-01
US10899736B2 (en)2021-01-26
IL276302B1 (en)2023-07-01
CN112105608A (en)2020-12-18
IL276302A (en)2020-09-30
CA3089832A1 (en)2019-08-08
EP3746429A1 (en)2020-12-09
AU2019213665A1 (en)2020-08-13
MA51771B1 (en)2022-03-31
MX2020007973A (en)2020-12-07
MD3746429T2 (en)2022-08-31
PL3746429T3 (en)2022-06-20
AU2019213665B2 (en)2024-06-13
CL2020001983A1 (en)2021-02-19
RS63312B1 (en)2022-07-29
ZA202004692B (en)2021-09-29
JP2021512163A (en)2021-05-13
EP3746429B1 (en)2022-03-09
WO2019152374A1 (en)2019-08-08
TWI797242B (en)2023-04-01
EP4086245A1 (en)2022-11-09

Similar Documents

PublicationPublication DateTitle
ZA202004692B (en)Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SG10202101949QA (en)Methods, apparatuses, and systems for human machine interface (hmi) operations
HUE062580T2 (en)Collet chuck
IL257282B (en)2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine compounds
IL247833B (en)2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
GB201710119D0 (en)Portable field maitenance tool configured for multiple process control communication protocols
ZA201606386B (en)2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
SG10201906214SA (en)Porous chuck table
IL262187B (en)Herbicidal pyridazinone compounds
ZA202002530B (en)Process for producing herbicidal pyridazinone compounds
IL288593A (en)Processes for preparing aminopyrimidine compounds
PL3623085T3 (en)Collet chuck
GB2579874B (en)Speakerphone configuration for conferencing
PL3648930T3 (en)Setting tool, set for a set tool system and set tool system
SI3438096T1 (en)Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione
ZA201808526B (en)Dynamically stabilizing intervertebral implant and tool for positioning same
GB2573561B (en)Alignment tool
AP01031S1 (en)Locking members for tools

[8]ページ先頭

©2009-2025 Movatter.jp